Insulin Resistance and Genetic Risk Predict Liver-Related Outcomes and Death in Nonalcoholic Fatty Liver Disease by Danford, Christopher J. et al.
1704
CORRESPONDENCE | Hepatology CommuniCations, Vol. 3, no. 12, 2019  
Insulin Resistance and Genetic Risk Predict Liver-Related 
Outcomes and Death in Nonalcoholic Fatty Liver Disease
TO THE EDITOR:
With a globally heightened awareness of nonalco-
holic fatty liver disease (NAFLD), the early identi-
fication of patients at risk for cirrhosis becomes an 
imperative. Current recommended risk-stratification 
strategy aims to capture liver fibrosis, a preclinical state 
of cirrhosis that predicts liver-related outcomes.(1) An 
alternative strategy is to use clinically measurable risk 
factors that drive NAFLD progression. We recently 
showed that a pathophysiological risk score (PRS) 
combining insulin resistance (IR) and genetic risk 
score can predict NAFLD histology.(2)
To validate this model built on cross-sectional 
observations, we evaluated whether the PRS predicts 
incident liver-related outcomes in the FINRISK 1992-
2012 and Health 2000 surveys, Finnish cross-sectional 
population surveys.(3) Subjects were linked with the 
National Registries for Hospitalizations, Death, and 
Cancer, to determine new diagnoses of cirrhosis, liver 
cancer, or liver-related mortalities.(4) Individuals with 
NAFLD at baseline, defined as a Fatty Liver Index 
score of 60 or higher,(5) were included. Individuals 
with at-risk drinking (>20 g of ethanol/day in women, 
>30 g/day in men), viral hepatitis, or other preexist-
ing liver diseases were excluded. The PRS at base-
line was calculated using age, homeostasis model 
assessment of IR (HOMA-IR), and the presence of 
risk alleles in PNPLA3 (patatin-like phospholipase 
domain containing 3) or TM6SF2 (transmembrane 6 
superfamily 2), using the equation from our previous 
study: PRS  =  0.072  *  age (years)  +  0.262  *  PNPLA 
(n alleles)  +  1.087  *  TM6SF2 (n alleles)  +  0.037  *   
(HOMA-IR/0.1006) − 0.1174.(2) Subjects were divided 
into PRS tertiles, and Kaplan-Meier analysis was per-
formed with liver-related events as the outcome.
Fig. 1. Cumulative incidence of advanced liver disease by Kaplan-Meier analysis stratified by tertiles of the pathophysiologic risk score. 
With a median follow-up of 13 years, most (68%) of the liver-related events occurred in the highest-risk tertile.
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Among 9,796 individuals with sufficient data to 
calculate the PRS, 2,740 (28%) had NAFLD and 
were included in the study (mean age of 57 years 
[SD = 12], 54% male, mean HOMA-IR = 3.6 [SD 6.8], 
38% PNPLA3 I148M carriers, and 12% TM6SF2 
E167K carriers). Over a median follow-up of 13 years 
(interquartile range 8-18), 28 incident liver-related 
events occurred in the NAFLD cohort, among whom 
19 (68%) happened in the highest-risk tertile of 
PRS (hazard ratio 3.95, 95% confidence interval 
1.57-9.91, compared with the lowest tertile) (Fig. 1). 
For comparison, there were 105 incident liver–related 
events in the general cohort of 9,796 individuals. The 
PRS showed moderate discrimination for incident 
liver events (C-statistic  =  0.704). A model consist-
ing of only age and HOMA-IR performed similarly 
(C-statistic = 0.699); however, the improved discrim-
ination with the addition of genetics was significant 
(P < 0.001 by likelihood-ratio test). Note that the dis-
criminant power of genetics is likely underestimated 
here, because the potential selection bias of the Fatty 
Liver Index favors NAFLD with conventional pheno-
types of high body mass index and fasting triglycerides 
over patients driven primarily by genetics.
In keeping with our growing knowledge, the obser-
vation here demonstrates that liver-related outcomes 
in NAFLD are largely predictable by genetics and IR 
in the general population. PRS, a non-liver-centric 
model based on the pathophysiology of NAFLD, is 
a viable strategy to risk-stratify NAFLD in the com-
munity especially, in places where access to specialty 
care is limited, and furthermore enables us to tackle 
the risk factors before development of advanced fibro-
sis in NAFLD.
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